drugset / Trial / NCT01253265

A Study in Rheumatoid Arthritis

NCT01253265

Phase 1 Completed 32 enrolled Eli Lilly and Company
RandomizedFactorialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of multiple doses of LY2439821 in Japanese patients with rheumatoid arthritis.

Timeline

Start
2010-05
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixekizumab Monoclonal antibody 30 mg Subcutaneous
Subject Ixekizumab Monoclonal antibody 80 mg Subcutaneous
Subject Ixekizumab Monoclonal antibody 120 mg Subcutaneous
Subject Ixekizumab Monoclonal antibody 180 mg Subcutaneous

Indications